A new research paper titled “Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival" has been published in Oncotarget.
2024
Cancer Vaccine for NSCLC and Melanoma Could Be Paradigm-Changing
The cancer vaccine, mRNA-4157, garnered immune responses of 30 weeks among some patients with melanoma and lung cancer, study results showed.
Free sunscreen offered at several popular Maine beaches as part of Harvard study
OLD ORCHARD BEACH, Maine — Approximately one person dies of melanoma every hour in the U.S., according to the American Cancer Society.
Individualized cancer therapy demonstrates safety and sustained immune responses
For decades, researchers have worked to develop therapies that can prime the immune system to recognize and attack proteins on the surface of tumor cells.